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Editorial on the Research Topic
Lymphocytes in MS and EAE: More Than Just a CD4+ World
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that affects 
nearly two million people worldwide. Disease onset can occur at a young age, leaving sufferers 
with a significantly reduced quality of life. The fact that there is no cure for MS, plus the fact 
that its animal model experimental autoimmune encephalomyelitis (EAE) is considered a “classic” 
model of CD4+ T cell-triggered autoimmunity, has led MS pathogenesis to be an area of intense 
investigation in the past few decades. Numerous lines of evidence indicate that MS is driven by 
CD4+ T lymphocyte-mediated mechanisms (1–3). Polymorphisms in the HLA class II region 
are by far the strongest genetic link to MS (4). Moreover, the majority of currently available MS 
disease-modifying therapies are believed to act by modulating inflammatory CD4+ T cell responses, 
although in many cases the effects on other immune cell types are under-studied and may be at 
least as important. Furthermore, while current immunomodulatory drugs are able to reduce the 
frequency and severity of MS relapses, they are relatively ineffective in progressive forms of the 
disease (5). Attempted blockade of CD4+ T cells using anti-CD4-depleting antibody therapy did 
not produce clinical benefits to patients with MS (6). In contrast, more global immunosuppressive 
or immunomodulatory approaches reduce the number of relapses and disease progression of MS 
patients (7). Furthermore, numerous publications have presented data generated from autopsy 
material obtained from human patients supporting the notion that other cell types are involved 
(8–11). There is thus an urgent need to expand our view of immune-related pathogenesis in human 
disease. Despite evidence that lymphocytes such as B cells and CD8+ T cells play a role, their 
contributions are much less well studied experimentally compared to those of CD4+ T cells. In 
this Special Topic, we promote this expanded view of disease pathogenesis by presenting articles 
that examine the role played by lymphocytes other than CD4+ T cells in MS and its experimental 
models.
The B cell-depleting reagents rituximab and ocrelizumab have shown success against relapsing/
remitting (12) and even progressive MS (13). Thus, it is no surprise that this collection features several 
submissions considering different aspects of potential B cell contributions to CNS autoimmunity. 
Both Claes et al. and Michel et al. survey what is known about B cells in MS and discuss potential 
pathogenic mechanisms including antibody production, cytokine secretion, antigen presentation 
to T cells, and the promotion of disease from within the CNS. Claes et al. additionally present a 
detailed review of how B cell subpopulations and effector functions are altered both by broadly 
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specific disease-modifying therapies such as interferon-beta and 
glatiramer acetate as well as by rituximab and ocrelizumab. B 
cell infiltration into the CNS in MS was a particular focus of the 
Michel et al. review, and this was further expanded upon by two 
additional reviews in this special topic. Blauth et al. describe the 
signals that may permit B cell entry to the CNS, such as CXCL13, 
VLA-4, and ICAM. Additionally, they discuss recent evidence 
suggesting that B cells can also exit the CNS so as to undergo 
additional affinity maturation in peripheral lymphoid tissues, as 
well as data indicating that the meninges can support differentia-
tion of CNS-specific B cells independently of the periphery. Once 
in the CNS, B cells have been described to form aggregates in 
the meninges akin to tertiary lymphoid organ-like structures, and 
these are the subject of a review from Pikor et al. In particular, 
they discuss recent evidence suggesting that antigen-experienced 
T and B cells accumulate in these structures to promote CNS 
inflammation.
A common theme of these reviews is the uncertainty regarding 
the neuropathogenic role of B cells in MS. Interestingly, evidence 
from the two primary research articles in this issue present a 
challenge to the hypothesis that autoreactive B cell responses are 
propagated within meningeal aggregates of lymphocytes. First, in 
an attempt to identify antigenic targets of B cell-mediated destruc-
tion in MS, Willis et al. cloned the IgV heavy and light chains of 
CNS-infiltrating B cell clones from six MS patients to generate 
putative CNS-reactive recombinant antibodies. Surprisingly, 
using various approaches (binding to candidate antigen, CNS cell 
lines, or antigen array) no CNS- or MS-specific antigen targets 
could be identified. Second, Dang et  al. present data showing 
that the presence of B cells in spinal cord-associated meningeal 
clusters correlates with chronic symptoms in a B cell-dependent 
model of spontaneous EAE. Intriguingly, however, these “cluster 
B cells” have a naïve phenotype with little evidence of Ig class 
switching and the clusters themselves do not bear the features 
of structured lymphoid follicles, suggesting that the simple pres-
ence of B cells in the meninges is sufficient to promote disease 
progression.
The remaining B cell-centric articles in this issue focus on 
other potential pathogenic mechanisms. B cells almost certainly 
shape the autoimmune response through the secretion of inflam-
matory cytokines such as TNFα, lymphotoxin, and GM-CSF, 
as described by Li et al. In addition, B cells can present antigen 
to T cells and modulate their properties. Márquez and Horwitz 
discuss the possibility that Epstein-Barr virus (EBV)-infected B 
cells preferentially elicit Th1 responses in the CNS. It is tempting 
to speculate that exposure to EBV, which is an environmental fac-
tor strongly associated with MS (14), influences disease outcomes 
by altering B cell activity. Furthermore, the effectiveness of B cell 
depletion therapy in MS may be due in part to reduced effec-
tor T cell function. While the “immune helper” functions of B 
cells in MS have been intensely investigated, the classic role of B 
cells as antibody-secreting cells cannot be neglected. Indeed, the 
presence of oligoclonal IgG bands in CSF has long been a clini-
cal biomarker of MS and is still used as a differential diagnostic 
tool (15). Khorooshi et al. detail what is known about antibody-
mediated pathogenic mechanisms in CNS autoimmunity. They 
pay particular attention to the role of anti-aquaporin 4 antibodies 
in neuromyelitis optica—a disease that has only recently been 
recognized as being independent of MS. They present a scheme 
in which these antibodies cross a disrupted blood–brain barrier 
and target astrocytes for complement-mediated destruction in a 
T cell-independent manner.
CD8+ T cells are present in MS tissue at all stages of disease. 
They can greatly outnumber CD4+ T cells in lesions, perivascular 
cuffs, and normal-appearing white matter. Furthermore, unlike 
CD4+ T cells that mostly remain restricted to the perivascular 
space, CD8+ T cells infiltrate deep into the CNS parenchymal 
lesions (16). Salou et al. delineate some of the current lines of 
investigation into the role of CD8+ T cells in MS, such as ongo-
ing efforts to characterize the antigenic repertoire of these cells, 
as well as recent advances in the study of CD8+ T cells using 
EAE and the importance of IL-17-producing CD8+ T cells in 
pathogenesis. Yang et  al. describe the pathogenic function of 
CD8+ T cells in peripheral neuropathies such as Guillain–Barré 
syndrome, with a particular emphasis on a mouse model that 
features CD8+ T cell-driven inflammation in the peripheral sci-
atic, trigeminal, and facial nerves. By contrast, Sinha et al. argue 
that the role of regulatory CD8+ T cells (Treg) in CNS autoim-
munity deserves further attention. Importantly, the frequency 
of CD8+ Treg is diminished during MS relapse, and the authors 
discuss findings suggesting that the drug glatiramer acetate 
may act, in part, by augmenting the CD8+ Treg response. Finally, 
Ignatius Arokia Doss et al. describe a transgenic mouse strain 
(1C6) in which both CD4+ and CD8+ T cells bear T cell receptor 
specificity to myelin antigen. The 1C6 transgene is on the NOD 
background, on which mice develop a relapsing-to-progressive 
pattern of EAE that models the form most commonly seen in 
human MS. The authors propose an approach in which 1C6 
CD8+ T cells are stimulated ex vivo with distinct differentiation 
stimuli, prior to adoptive transfer. This would allow one to 
dissect the relative contributions of IFNγ-producing, IL-17-
positive, and potentially even regulatory CD8+ T cells to CNS 
autoimmunity.
While B cells and CD8+ T cells represent two-thirds of the 
lymphocytic “Holy Trinity,” there is an array of other lymphocyte 
subsets with innate immune-like properties that have been pos-
ited to play a role in MS. Edwards et al. and Malik et al. provide 
an overview of what is known about γδ T cells in MS and EAE, 
respectively. These cells, which are found principally in skin and 
mucosal tissues, readily produce IL-17-associated cytokines and 
thus may be important mediators of inflammation in the CNS. 
The role of natural killer cells in disease may be Janus-like, with 
inflammatory CD16+CD56dim cells being increased during MS 
relapse while the CD16dim/-CD56bright subset predominates during 
remission (Edwards et  al.). Treiner and Liblau report what is 
known about recently identified mucosal-associated invariant T 
(MAIT) cells. These are lymphocytes with innate properties that, 
as their name suggests, are located in mucosal tissues such as in 
the gut. While studies in mouse EAE have suggested that MAIT 
cells are anti-inflammatory, the picture is less clear in humans as 
MS immunotherapy appears to affect the frequency of peripheral 
MAIT cells. However, as MAIT cells may proliferate in response 
to commensal microbial antigens (17), it is tempting to speculate 
that they may provide part of the answer to the question of 
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how the microbiome can influence autoimmune inflammatory 
diseases such as MS.
The past decades have seen remarkable progress in unraveling 
the complex and diversified immune mechanisms that contribute 
to MS pathobiology. Nevertheless, the precise etiology of MS 
remains elusive. Furthermore, despite an increasing number of 
immunomodulatory or immunosuppressive therapies altering 
relapsing-remitting MS, there is a pressing need for effective 
treatments for progressive disease. The more expanded view of 
disease pathology presented in this Special Topic may prove to be 
the key for the next generation of MS therapies.
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